Document Detail


Combination cefixime/amoxicillin against penicillin-resistant Streptococcus pneumoniae infection.
MedLine Citation:
PMID:  9797416     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The rising incidence of antibiotic resistance, including penicillin-resistant Streptococcus pneumoniae (PRSP), has become a great clinical problem in many countries. Cefixime, an orally active third-generation cephalosporin has broad and potent activity against various pathogens, especially gram-negative organisms including beta-lactamase producing strains. However, as with all other oral agents, cefixime is inactive against PRSP. As a possible solution to this problem, the effectiveness of a combination of cefixime and amoxicillin which retains stronger activity against PRSP was evaluated. This combination worked synergistically against S. pneumoniae including PRSP by the checkerboard method with a mean FIC index value of 0.60 and the time-kill kinetic method. Similarly, a synergistic effect was shown in the mouse respiratory tract infection model, with an FED index of 0.29 (cefixime:amoxicillin = 2:1). Additionally, this combination showed excellent activity against mixed organisms including PRSP, in the human serum level simulating kinetic method and mouse respiratory mixed infection models. We review here briefly preclinical studies carried out in our laboratory which demonstrate the synergistic effect of this cefixime plus amoxicillin combination, and suggest the empirical therapeutic potency of this combination for treating community-acquired respiratory tract infections, including PRSP, in the clinical setting.
Authors:
Y Matsumoto
Related Documents :
12951336 - Considering resistance in systematic reviews of antibiotic treatment.
10553706 - Quinolones in the treatment of typhoid fever.
8346736 - Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia durin...
10991866 - Effects of antiviral usage on transmission dynamics of herpes simplex virus type 1 and ...
17642976 - In vitro activity of cefpirome: a new fourth generation cephalosporin.
15964496 - Reevaluation of the cefepime minimal inhibitory concentrations and disk diffusion test ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Chemotherapy     Volume:  44 Suppl 1     ISSN:  0009-3157     ISO Abbreviation:  Chemotherapy     Publication Date:  1998 Sep 
Date Detail:
Created Date:  1998-12-11     Completed Date:  1998-12-11     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0144731     Medline TA:  Chemotherapy     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  6-9     Citation Subset:  IM    
Affiliation:
Department of Infectious Diseases, Medicinal Biology Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amoxicillin / administration & dosage,  pharmacology*
Animals
Cefixime
Cefotaxime / administration & dosage,  analogs & derivatives*,  pharmacology
Cephalosporins / administration & dosage,  pharmacology*
Drug Synergism
Drug Therapy, Combination
Humans
Mice
Penicillin Resistance*
Penicillins / administration & dosage,  pharmacology*
Pneumococcal Infections / drug therapy*
Respiratory Tract Infections / drug therapy
Streptococcus pneumoniae / drug effects*,  pathogenicity
Chemical
Reg. No./Substance:
0/Cephalosporins; 0/Penicillins; 26787-78-0/Amoxicillin; 63527-52-6/Cefotaxime; 79350-37-1/Cefixime

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Overview of the clinical features of cefixime.
Next Document:  New perspectives offered by a French study of antibiotic resistance in day-care centers.